Alnylam Initiates Phase 1/2 Clinical Trial for ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 )--Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that it has initiated a Phase 1/2 clinical trial with ALN-GO1... )--Lenovo and Juniper Networks , the industry leader in network innovation, today announced the comm... )--Granite Construction Incorporated announced today that the joint venture team comprised of Granite Construction Company, Fluor Corporation and Ames ... )--Junior Achievement USA last night honored U.S. Bank's Leslie Godridge with its Gold Leadership Award, the organization's highest recognition, for her volunteer work ... )--Daniel Flynn, Ph.D., Deciphera's Chief Scientific Officer and Founder will give a plenary talk at the upcoming 251st National Meeting & Exposition of the American C...
↧